Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines
Cédric Rossi, Guillaume Manson, Amira Marouf, Aurélie Cabannes-Lamy, Emmanuelle Nicolas‐Virelizier, Marie Maerevoet, Marion Alcantara, Lysiane Molina, Antony Ceraulo, Marilyne Poirée, Jean Galtier, Nadia Diop, Caroline Delette, Amandine Ségot, Sydney Dubois, Agathe Waultier, Sophie Bernard, Robin Noël, Stéphanie Guidez, Milena Kohn, Sébastien Bailly, Hannah Moatti, Mohamed Touati, Loïc Renaud, Salim Kanoun, Anne‐Ségolène Cottereau, Youlia Kirova, Karine Peignaux, Marie-Émilie Dourthe, Mathieu Simonin, Thierry Leblanc, L. Quéro, Daphné Krzisch, Rémy Duléry, Adrien Grenier, Thomas Gastinne, Olivier Casasnovas, Andrea Gallamini, Marc André, Franck Morschhauser, Bénédicte Deau, Luc-Mathieu Fornecker, Hervé Ghesquières
Abstract
Classic Hodgkin lymphoma (HL) is a distinct entity among hematological malignancies of B-cell origin. It is characterized by its unique histopathological features and generally favorable prognosis. Over the years, advancements in understanding its pathogenesis, coupled with refined diagnostic and evaluation modalities, as well as therapeutic strategies, have significantly transformed the landscape of HL management. In this article, we present a comprehensive set of recommendations for the management of HL, encompassing various aspects of diagnosis, risk stratification, evaluation, and treatment. These recommendations are based on the latest evidence-based guidelines, expert consensus opinions, and clinical trial data, aiming to provide clinicians with a practical framework for delivering optimal care to patients with HL.